Listar por tema "soft tissue infection"
Mostrando ítems 1-7 de 7
-
Clinical Experience with Daptomycin for the Treatment of Gram-positive Infections in Children and Adolescents
(2016)Background: This subgroup analysis of the European Cubicin Outcomes Registry Experience evaluated the safety and effectiveness of daptomycin in children and adolescent patients (<18 years). Methods: Clinical outcomes at ... -
Daptomycin Use in Children: Experience with Various Types of Infection and Age Groups
(2017)Background: In Greece, there are high rates of methicillin (40%-60%) and clindamycin (15%-25%) resistance among community-acquired Staphylococcus aureus isolates. Therefore, we sought to identify other antimicrobial treatment ... -
Emergence of a mupirocin-resistant, methicillin-susceptible Staphylococcus aureus clone associated with skin and soft tissue infections in Greece
(2021)Background: Staphylococcus aureus causes various infections, including skin and soft tissue infections (SSTIs). In this study, methicillin-susceptible S. aureus (MSSA) from SSTIs among patients in three tertiary-care ... -
Management strategies for prosthetic joint infection: long-term infection control rates, overall survival rates, functional and quality of life outcomes
(2021)DAIR (debridement, antibiotics, and implant retention), one-stage and two-stage revision surgery are the most common management strategies for prosthetic joint infection (PJI) management. Our knowledge concerning their ... -
Mutations conferring colistin resistance development in Acinetobacter baumannii clinical isolates
(2013)The colistin resistance mechanisms in Acinetobacter baumannii are largely unknown. In the present study, we investigated the characteristics and the mechanisms of colistin resistance in two genetically indistinguishable ... -
Outcome of refractory to conventional and/or biologic treatment adult Still's disease following canakinumab treatment: Countrywide data in 50 patients
(2021)Objective: To assess the efficacy and safety of the IL-1b inhibitor canakinumab in all adults with refractory Still's disease identified from the National Organization For Medicines for off-label drug use. Methods